GLOBAL PERSPECTIVES ON ADR MONITORING: A COMPARATIVE REVIEW OF PHARMACOVIGILANCE SYSTEM
Authors/Creators
- 1. Rajarambapu College of Pharmacy, Kasegaon, Sangli, Maharashtra India.
Description
Pharmacovigilance (PV) is necessary to implement drug safety measures and reduce adverse drug reactions all over the world. This review compares pharmacovigilance practices in various countries, including India, the United States, Malaysia, Singapore, Thailand, China, Nepal, Australia and European countries, highlighting the global nature of ADR surveillance systems. This study highlights the development of PV systems, their current status and the challenges they face, such as low reporting, lack of national recognition, varying regulatory frameworks and regulatory shortcomings. While developed countries generally have more mature systems, many developing countries are still building capacity. The part of the World Health Organization (WHO) in social development safety efforts is highlighted. A comparative analysis effectively reveals common barriers to ADR, including a lack of proper training, public reporting processes and low participation. Future directions Take advantage of emerging technologies such as AI, increase global assistance rates and reporting, and suggest disease-focused approaches to improve data quality. Improving drug safety surveillance systems is crucial to ensuring the safety of safe forms and enhancing clinical outcomes globally.
Files
13 WJPSR 1815.pdf
Files
(737.7 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:d94f7c8ffaad301d60d3c7b631411b3d
|
737.7 kB | Preview Download |
Additional details
References
- 1. Dutta A, Banerjee A, Basu S, Chaudhry S. Analysis of under-reporting of Adverse Drug Reaction: Scenario in India and neighbouring countries. IP Int J Comprehensive Adv Pharmacol, 2020; 5(3): 118-124.
- 2. Swapnil. Shinde*, Vyankatesh Dharanguttikar, Swapnali Dharanguttikar, Parag Shinde, Pratiksha Mahajan, Pratik Shitole, Comparative Review of Pharmacovigilance System in Different Countries, Int. J. of Pharm. Sci., 2025; l3(2): 1628-1636. https://doi.org/10.5281/zenodo.14892698
- 3. Reza S.M.Rabbur and Lynne Emmerton An introduction to adverse drug reaction reporting systems in different countries March International Journal of Pharmacy Practice, 2005; 13(1). DOI:10.1211/0022357055821
- 4. Dutta A, Banerjee A, Pramanik P, Pradhan N, Chaudhry S. Pharmacovigilance in India and five ASEAN countries (Malaysia, Singapore, Thailand, Indonesia, Philippines): A comparison study. IP Int J Comprehensive Adv Pharmacol, 2021; 6(1): 1-4.
- 5. Sachdev Yadav status of adverse drug reaction monitoring and Pharmacovigilance in selected countries- Indian J Pharmacol, 2008 Feb; 40(Suppl1): S4–S9. PMCID: PMC3038524 PMID: 21369413
- 6. Suyagh, M., Farah, D., & Farha, R. A., Pharmacist's knowledge, practice and attitudes toward pharmacovigilance and adverse drug reactions reporting process. Saudi Pharmaceutical Journal, 2015; 23(2): 147-153.
- 7. Jyothi DB, Swetha K. Knowledge awareness and practice of pharmacovigilance among health-care providers at a tertiary care hospital – A questionnaire-based study. Natl J Physiol Pharm Pharmacol, 2020; 10(03): 270-275.
- 8. Patricia García-Abeijon, Catarina Costa, Margarita Taracido, Maria Teresa Herdeiro, Carla Torre, Adolfo Figueiras- Factors Associated with Underreporting of Adverse Drug Reactions by Health Care Professionals: A SysPtematic Review Update PMCID: PMC10279571 PMID: 37Drug Saf., 2023 Jun 6; 46(7): 625–636. doi: 10.1007/s40264-023-01302-7277678
- 9. Maysa Suyagh, Doaa Farah, Rana Abu Farha - Pharmacist's knowledge, practice and attitudes toward pharmacovigilance and adverse drug reactions reporting processSaudi Pharmaceutical Journal, April 2015; 23(2): 147-153, https://doi.org/10.1016/j.jsps.2014.07.001
- 10. Tze Seong Chen, Kien Seang Kwong, Sai Hong Lee, Noor Ashikin Nordin, Chiew Ping Tan, Mohd Faiz Mohd Wahiza, Yi Heng Lim, Nurul Syahamah Shakar and Nuraini Arshad, Knowledge, Practices & Attitudes Towards Adverse Drug Reaction Reporting among Public Healthcare Professionals in West Pahang. Malaysian Journal of Pharmacy (MJP), 2023; 2(9): 29-36. https://mjpharm.org/knowledge-practices-attitudes-towards-adverse-drug-reaction-reporting-among-public-healthcare-professionals-in-west-pahang/
- 11. https://nanoschool.in/nstc-blog/challenges-and-opportunities-in-pharmacovigilance-navigating-complexities-and-ensuring-compliance/#:~:text=Pharmacovigilance%20faces%20several%20challenges%2C%20but,%2C%20electronic%20health%20records%2C%20wearables.
- 12. ANBEO, Z. G., & ABACIOĞLU, N., A Systematic Review of Healthcare Professionals' Knowledge, Attitudes, and Practices Regarding Adverse Drug Reaction Reporting in Ethiopia. Turkish Journal of Pharmaceutical Sciences, 2023; 20(3): 198-209. https://doi.org/10.4274/tjps.galenos.2022.28034
- 13. Anant Khot and Ganesh Dakhale-Challenges and Possible Solutions of ADR Monitoring (Pharmacovigilance) in Low- and Middle-Income Countries DOI: 10.5772/intechopen.1006043
- 14. Zaka Un Nisa, Ayesha Zafar, Farooq Sher -Assessment of knowledge, attitude and practice of adverse drug reaction reporting among healthcare professionals in secondary and tertiary hospitals in the capital of Pakistan -Saudi Pharmaceutical Journal, May 2018; 26(4): 453-461n -https://doi.org/10.1016/j.jsps.2018.02.014
- 15. https://www.google.com/search?q=adr+monitoring+ratio+in+europe&rlz=1C1CHBF_enIN830IN830&oq=adr+monitoring+ratio+in+eu&aqs=chrome.1.69i57j33i160l2.20472j0j15&sourceid=chrome&ie=UTF-8 https://english.nmpa.gov.cn/2021 https://english.nmpa.gov.cn/2021-03/26/c_654833.htm-03/26/c_654833.htm
- 16. Haibo Song, Xiaojing Pei, Zuoxiang Liu, Chuanyong Shen, Jun Sun, Yuqin Liu, Lingyun Zhou, Feng Sun, Xiaohe XiaoPharmacovigilance in China: Evolution and future challenges: British journal of clinical pharmacology https://doi.org/10.1111/bcp.15277
- 17. World Health Organization (WHO). The Importance of Pharmacovigilance: Safety Monitoring of Medicinal Products. WHO, 2002.
- 18. Edwards IR & Aronson JK. Adverse drug reactions: definitions, diagnosis and management. The Lancet, 2000; 356(9237): 1255–1259.
- 19. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis. JAMA, 1998; 279(15): 1200–1205.
- 20. Rabbur SMR, Emmerton L. An introduction to ADR reporting systems in different countries. Int J Pharm Pract, 2005; 13(1): 91–100.
- 21. Waller P. An introduction to pharmacovigilance. Wiley-Blackwell, 2010.
- 22. Uppsala Monitoring Centre (WHO Program).WHO Programme for International Drug Monitoring. WHO-UMC, 2018. (Use for the 1968 WHO PIDM reference and thalidomide history.)